Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

Fragility fractures are common and increase morbidity and mortality. Romosozumab (Amgen and UCB Pharma) is a new bone-forming monoclonal antibody that binds to and inhibits sclerostin, with a dual effect of increasing bone formation and decreasing bone resorption. In a randomized, controlled trial,…

http://ift.tt/2xteNfY